Neofact® - Feasibility study

In the clinical study carried out at the University Hospital Tübingen, 20 premature infants (gestational age ≥26 + 0/7) were administered surfactant Alveofact® (45 mg / mL; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid Neofact®. The aim of developing Neofact® was to enable a simple and gentle process for surfactant application that works without the use of Magill forceps. Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing. An extremely high success rate could be achieved (95%), complications seemed rear.

Further information on the study can be found: https://pubmed.ncbi.nlm.nih.gov/33023914/